VIA EDGAR
June 4, 2024
United States Securities and Exchange Commission
Division of Corporation Finance
Office of Life Sciences
100 F. Street, N.E.
Washington, D.C. 20549
Attention: Tamika Sheppard, Joe McCann, Daniel Gordon and Jenn Do
| Re: | Rapport Therapeutics, Inc. |
Acceleration Request for Registration Statement on Form S-1
File No. 333-279486
Dear Ladies and Gentlemen,
Pursuant to Rule 461 under the Securities Act of 1933, as amended (the “Act”), Rapport Therapeutics, Inc. (the “Company”) hereby requests that the effective date of the above-referenced registration statement (the “Registration Statement”) be accelerated to June 6, 2024 at 4:00 p.m. Eastern Time, or as soon thereafter as practicable, unless we or our outside counsel, Goodwin Procter LLP, request by telephone that such Registration Statement be declared effective at some other time. In making this acceleration request, the Company acknowledges that it is aware of its responsibilities under the Act.
Once the Registration Statement is effective, please orally confirm the event with our counsel, Goodwin Procter LLP, by calling Justin S. Platt at (212) 459-7340.
If you have any questions regarding this request, please contact Justin S. Platt of Goodwin Procter LLP at (212) 459 7340.
Sincerely,
RAPPORT THERAPEUTICS, INC.
/s/ Troy Ignelzi
Troy Ignelzi
Chief Financial Officer
| cc: | Abraham N. Ceesay, Rapport Therapeutics, Inc. |
Kingsley L. Taft, Goodwin Procter LLP
Stephanie A. Richards, Goodwin Procter LLP
Justin S. Platt, Goodwin Procter LLP